帕博利珠单抗联合索拉非尼治疗转移性肝细胞癌完全缓解：一例报告 - Suppr

Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.

作者信息

Chen San-Chi, Chao Yee, Yang Muh-Hwa

机构信息

Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.

出版信息

Am J Gastroenterol. 2017 Apr;112(4):659-660. doi: 10.1038/ajg.2017.1.

DOI:10.1038/ajg.2017.1

PMID:28381841

Abstract

摘要

相似文献

Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.

Am J Gastroenterol. 2017 Apr;112(4):659-660. doi: 10.1038/ajg.2017.1.

The role of sorafenib in hepatocellular carcinoma.

Clin Adv Hematol Oncol. 2015 Apr;13(4):232-4.

Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.

J Gastrointest Cancer. 2013 Mar;44(1):98-101. doi: 10.1007/s12029-012-9438-6.

Treatment of advanced hepatocellular carcinoma: beyond sorafenib.

Lancet Gastroenterol Hepatol. 2018 Apr;3(4):218-220. doi: 10.1016/S2468-1253(17)30255-8. Epub 2018 Mar 7.

Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.

J Gastrointest Cancer. 2015 Dec;46(4):430-3. doi: 10.1007/s12029-015-9720-5.

AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.

Gastroenterology. 2022 Mar;162(3):937-951. doi: 10.1053/j.gastro.2021.12.275.

Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.

World J Gastroenterol. 2014 Jan 7;20(1):235-41. doi: 10.3748/wjg.v20.i1.235.

Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.

J Dig Dis. 2015 Sep;16(9):537-40. doi: 10.1111/1751-2980.12270.

Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.

Asian Pac J Cancer Prev. 2014;15(2):1063. doi: 10.7314/apjcp.2014.15.2.1063.

[Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].

Presse Med. 2013 Feb;42(2):235-7. doi: 10.1016/j.lpm.2012.02.005. Epub 2012 Mar 16.

引用本文的文献

Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.

Front Oncol. 2022 Aug 2;12:816198. doi: 10.3389/fonc.2022.816198. eCollection 2022.

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.

BMC Cancer. 2022 Jan 11;22(1):55. doi: 10.1186/s12885-022-09173-4.

Advanced hepatocellular carcinoma treated by radiofrequency ablation combined with oncolytic virus and anti-PD-1 antibody therapy: a case report and literature review.

J Int Med Res. 2021 Sep;49(9):3000605211044596. doi: 10.1177/03000605211044596.

The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.

Oncologist. 2021 Jun;26(6):e1036-e1049. doi: 10.1002/onco.13638. Epub 2021 Jan 2.

Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?

Angiogenesis. 2020 Nov;23(4):543-557. doi: 10.1007/s10456-020-09734-w. Epub 2020 Jul 20.

Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.

Front Pharmacol. 2019 Oct 17;10:1173. doi: 10.3389/fphar.2019.01173. eCollection 2019.

Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.

Clin Transl Oncol. 2019 Jun;21(6):702-712. doi: 10.1007/s12094-018-1975-4. Epub 2018 Nov 1.

Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study.

PLoS One. 2017 Nov 10;12(11):e0188031. doi: 10.1371/journal.pone.0188031. eCollection 2017.

本文引用的文献

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.

Hepatology. 2016 Dec;64(6):2038-2046. doi: 10.1002/hep.28710. Epub 2016 Aug 9.

Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.

Immunotherapy. 2016;8(3):299-313. doi: 10.2217/imt.15.126. Epub 2016 Feb 11.

Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.

Int J Cancer. 2014 Jan 15;134(2):319-31. doi: 10.1002/ijc.28362. Epub 2013 Jul 30.

Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.

Lab Invest. 2011 Apr;91(4):598-608. doi: 10.1038/labinvest.2010.205. Epub 2011 Feb 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献